Early (n=36)

Late (n=10)

P-value

Site of infection – n (%)

       Pulmonary

       Intra-abdominal

       Urinary tract

       Bone/Joint

       Cardiac/Endocarditis

       Line/Bloodstream

       Skin and soft tissue

       Other

12 (33.3)

12 (33.3)

2 (5.6)

0 (0)

0 (0)

2 (5.6)

0 (0)

8 (22.2)

7 (70)

0 (0)

0 (0)

0 (0)

0 (0)

2 (20)

0 (0)

1 (10)

0.0672

0.0439

0.9999

0.9999

0.9999

0.2015

0.9999

0.6590

Need for MV during course of vasopressor therapy – n (%)

33 (91.6)

10 (100)

0.5489

Need for RRT during course of vasopressor therapy – n (%)

21 (58.3)

6 (60)

0.9999

Concomitant medications during course of vasopressor therapy – n (%)

       Ascorbic acid, thiamine, hydrocortisone

       Hydrocortisone monotherapy

       Midodrine

       Intravenous sodium bicarbonate

       Dobutamine

       Milrinone

       Propofol

       Midazolam

21 (58.3)

6 (16.6)

4 (11.1)

6 (16.7)

12 (33.3)

4 (11.1)

2 (5.6)

7 (47.2)

6 (16.7)

4 (40)

3 (30)

3 (30)

0 (0)

7 (70)

1 (10)

0 (0)

3 (30)

3 (30)

0.4748

Fluids administered prior to vasopressor therapy – mL/kg, median (SD)

41.6 (23.2)

35.3 (11.9)

0.6534

First adjunctive vasopressor initiated – n (%)

       Phenylephrine

       Vasopressin

3 (8.3)

33 (91.6)

1 (10)

9 (90)

0.9999

Norepinephrine dose at time of first adjunctive vasopressor initiation – mcg/kg/min, median (IQR)

0.875 (0.375, 1.25)

2 (2, 2)

<0.001

                                       -- mcg/min

55.3175

127.2

<0.001

MAP at the time of adjunctive vasopressor initiation – mmHg, median (SD)

69 (13.6)

59.5 (11.2)

0.1475

Median total number of concomitant vasopressors

3

3

0.0695